Cargando…
A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers
PURPOSE: To evaluate the ocular safety of OTX-101 0.09% – a novel, nanomicellar, clear, aqueous solution of cyclosporine (CsA) – and to determine the systemic exposure to CsA following ophthalmic administration. PATIENTS AND METHODS: Healthy volunteers ≥18 years of age were recruited for participati...
Autores principales: | Karpecki, Paul M, Weiss, Sidney L, Kramer, William G, O’Connor, Patrick, Evans, David, Johnston, Josh, Jasper, April L, Justice, Angela, Ogundele, Abayomi B, Devries, Doug |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454998/ https://www.ncbi.nlm.nih.gov/pubmed/31040639 http://dx.doi.org/10.2147/OPTH.S187945 |
Ejemplares similares
-
Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
por: Sheppard, John, et al.
Publicado: (2021) -
Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies
por: Malhotra, Ranjan, et al.
Publicado: (2019) -
Ocular Distribution of Cyclosporine Following Topical Administration of OTX-101 in New Zealand White Rabbits
por: Weiss, Sidney L., et al.
Publicado: (2019) -
Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
por: Karpecki, Paul, et al.
Publicado: (2023) -
Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White, Darrell E, et al.
Publicado: (2019)